Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The inspection closed with zero observations
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Unani Medicine facilities to be upgraded at Hyderabad, Chennai, Lucknow, Silchar and Bengaluru
5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience
Subscribe To Our Newsletter & Stay Updated